How metabolism affects immune responses in breast cancer
Metabolic Control of Innate and Adaptive Immunity in Breast Cancer
This study is looking at how certain immune cells in breast cancer patients can make it harder for the body to fight the cancer, and it aims to find new ways to boost the immune system's response to tumors by understanding the role of metabolism in these processes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10925144 on NIH RePORTER |
What this research studies
This research investigates the role of metabolic processes in regulating both innate and adaptive immunity in patients with breast cancer. It focuses on understanding how certain immune cells, particularly regulatory T cells (Treg), create an immunosuppressive environment that hinders effective cancer treatment. By studying the mechanisms through which these Treg cells induce senescence in other immune cells, the research aims to develop new strategies to enhance the immune response against breast tumors. The approach includes analyzing the metabolic pathways that influence immune cell function and exploring ways to reverse the suppressive effects of Treg cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced breast cancer who are seeking new treatment options.
Not a fit: Patients with early-stage breast cancer or those not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy strategies for breast cancer patients, enhancing their chances of recovery.
How similar studies have performed: Other research has shown promising results in manipulating immune cell metabolism to improve cancer treatment outcomes, suggesting that this approach may be effective.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Peng, Guangyong — Washington University
- Study coordinator: Peng, Guangyong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.